About UroGen
UroGen is a publicly listed company based in Raanana (Israel) founded in 2004. UroGen is focused on developing treatments for urological cancers. It operates on a HealthTech model. UroGen has raised $7 million across 4 funding rounds from investors including RTW Investments, RA Capital and Great Point Partners. The company has 235 employees. Its chief executive, as recorded, is Ron Bentsur. UroGen offers products and services including Zusduri™ (mitomycin), Jelmyto® (mitomycin), and RTGel® Technology. Its focus areas include Biotechnology and Oncology. Its legal entity is UroGen Pharma, Ltd.
Company details
UroGen is dedicated to the development of innovative therapies for urological cancers. Solutions are provided through breakthrough technologies like RTGel for drug delivery. The portfolio includes Zusduri and Jelmyto, targeting non-muscle invasive bladder cancer and pyelocalyceal conditions. The sector of operation is primarily healthcare, with a focus on oncology. Research and clinical trials are conducted to address unmet needs in uro-oncology. Partnerships and pipeline expansions are pursued to enhance treatment possibilities.
- Headquarters Raanana, Israel
- Employees 235
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website urogen.com
- Social LinkedIn X
- Legal Name Urogen Pharma Ltd.
- Annual Revenue$109.79 M (USD)21.45as on Dec 31, 2025
- Net Profit-$153.49 M (USD)-20.98as on Dec 31, 2025
- EBITDA-$122.45 M (USD)-28.09as on Dec 31, 2025
- Total Equity Funding$7M (USD)
in 4 rounds
- Latest Funding Round$120M (USD), Post-IPO
Jul 2023
- InvestorsRTW Investments
& 7 more
- Employee Count235
Products & Services of UroGen
UroGen offers a comprehensive portfolio of products and services, including Zusduri™ (mitomycin), Jelmyto® (mitomycin), and RTGel® Technology.
Used for treating non-muscle invasive bladder cancer.
Applied for pyelocalyceal solution in uro-oncology treatment.
Innovative technology used for drug delivery solutions.
Funding Insights of UroGen
UroGen has successfully raised a total of $7M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $120 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7M
- Total Rounds 4
- Last Round Post-IPO — $120M
- First Round $7M
(May 2013)
- Investors Count 8
All 4 funding rounds of UroGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $120M | Post-IPO | – | – | |
| Mar 2021 | $75M | Post-IPO | – | – | |
| Jun 2016 | Series B | – | Sonostar Ventures | – | |
| May 2013 | $7M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in UroGen
UroGen has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include RTW Investments, RA Capital and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
| acornbioventures.com | ||||
Monograph Capital is focused on life sciences investment. | monograph.bio | |||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital investment in private companies and start-ups across various industries, including biotechnology and direct-to-consumer sales. | sonostarventures.com | |||
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
| hortoncapital.com |
Investor details for UroGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of UroGen
93 people are tracked at UroGen (48 in leadership, 8 in board & advisors, 37 in team); the tracked headcount is 235.
| Name | Role | Group |
|---|---|---|
Ron Bentsur | CEO | Leadership |
Keren Stotzky | VP Manufacturing and Supply chain | Leadership |
Charlie Beck | Director, Supply Chain | Leadership |
Jacob Mani | Head Distribution Chain And Enterprise Systems | Leadership |
L Veronica Lee | Vice President Medical Affairs | Leadership |
Jennifer Lio | Director Of Learning And Development | Leadership |
Alexis Ilardi | Director, Marketing, Ugn-102 | Leadership |
Sheli Heksch-Agassi | Director, Israel Operations and Human Resources | Leadership |
Michal Rotem Helman | Director of Quality Operations | Leadership |
Nikhil Sharma | Director, Forecasting & Portfolio Analytics | Leadership |
Brasse, Fazela | Director, Human Resources | Leadership |
Silvio Pacheco | Vice President, Market Access | Leadership |
Will Batenic | Vice President Of Sales And Sales Operations | Leadership |
Michael Toohey | Director Compliance | Leadership |
Dominick Gagliostro | Vice President-Project Management and Regulatory Operations | Leadership |
Benny Cohen | Director, Pharmaceutical Research And Development | Leadership |
Peter Maruszewski | Vice President Supply Chain | Leadership |
Jason Smith | General Counsel & Chief Compliance Officer | Leadership |
Liz Barrett | President & CEO | Leadership |
Mark P. Schoenberg | Chief Medical Officer | Leadership |
73 more people are available in the full profile.
Complete people profiles for UroGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of UroGen
UroGen is a publicly listed company on the NASDAQ with ticker symbol URGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 May 2017
- Listed onNASDAQ: URGN
- Listed entityUroGen Pharma Ltd.
- Exchange sectorHealth technology
- ISINIL0011407140
- Share price$38.26 (-0.05% on the day) · 2026-10-13
- Market capitalisation$1.87B
- EPS (diluted, trailing year)$-1.99
- Volume (last session)759,912
Financials of UroGen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $109.8M | -$153.5M | -$122.5M |
| 2024 | $90.4M | -$126.9M | -$95.6M |
| 2023 | $82.7M | -$102.2M | -$63.8M |
| 2022 | $64.4M | -$109.8M | -$77.2M |
| 2021 | $48.0M | -$110.8M | -$90.5M |
Detailed financial statements for UroGen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of UroGen
4 dated milestones of UroGen across 19 years, from founding to its latest funding, stage changes and deals.
- Founded UroGen is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $120.0M.
Web traffic of UroGen
The website of UroGen (urogen.com) receives about 9.3K visits a month and ranks #2,761,473 among all websites worldwide, #3,719 in Biotechnology and Pharmaceuticals.
- Monthly visits9.3K
▲ 11.7% vs previous month
- Unique visitors3.6K
per month
- Global rank#2,761,473
among all websites
- Category rank#3,719
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.4
- Average visit20 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with UroGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ibnsinafoundation.org | ibnsinafoundation.org | 100% | #1,874,080 | – | |
| thetriminator.com | 91% | 11.8K | #1,812,722 | View details | |
firstwordpharma.com | firstwordpharma.com | 91% | #237,108 | – | |
| rocketseeds.com | 91% | #935,455 | View details | ||
onclive.com | onclive.com | 91% | #306,443 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for UroGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Urogen
Complete news archive for UroGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UroGen
UroGen was founded in 2004 and raised its 1st funding round 9 years after it was founded.
UroGen is headquartered in Raanana, Israel. It is registered at Raanana, Central District, Israel.
Ron Bentsur is the CEO of UroGen, as recorded in our data.
UroGen is a funded company, having raised a total of $7M across 4 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on May 2013.
UroGen has 235 employees.
Annual revenue of UroGen is $109.79M as on Dec 31, 2025.
UroGen is dedicated to the development of innovative therapies for urological cancers. Solutions are provided through breakthrough technologies like RTGel for drug delivery. The portfolio includes Zusduri and Jelmyto, targeting non-muscle invasive bladder cancer and pyelocalyceal conditions. The sector of operation is primarily healthcare, with a focus on oncology. Research and clinical trials are conducted to address unmet needs in uro-oncology. Partnerships and pipeline expansions are pursued to enhance treatment possibilities.
UroGen offers Zusduri™ (mitomycin), Jelmyto® (mitomycin), and RTGel® Technology.
Yes, UroGen is publicly traded on NASDAQ under the ticker symbol URGN.
UroGen has 8 investors. Key investors include RTW Investments, RA Capital, Great Point Partners, Acorn Bioventures, and Monograph Capital.
UroGen operates through Urogen Pharma, Ltd..